Afficher la notice abrégée

Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation

dc.rights.licenseopenen_US
dc.contributor.authorBLIN, Patrick
dc.contributor.authorDUREAU-POURNIN, C.
dc.contributor.authorCOTTIN, Y.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBENICHOU, Jacques
dc.contributor.authorMISMETTI, P.
dc.contributor.authorABOUELFATH, A.
dc.contributor.authorLASSALLE, Regis
dc.contributor.authorDROZ, C.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOORE, Nicholas
dc.date.accessioned2020-05-19T08:35:52Z
dc.date.available2020-05-19T08:35:52Z
dc.date.issued2019
dc.identifier.issn1532-6535 (Electronic) 0009-9236 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/7636
dc.description.abstractEnDabigatran and rivaroxaban at standard (SD) or reduced doses (RD) have been compared to warfarin in non-valvular atrial fibrillation (NVAF), but not to each other. This was a new user study of SD and RD dabigatran or rivaroxaban for NVAF in the French healthcare database, matched on gender, age, date of first dispensing, and high-dimensional propensity score, followed 2 years. Hazard ratios [95% Confidence Intervals] of stroke or systemic embolism (SSE), major bleeding (MB) or death, were computed. In matched SD patients (8,290 per arm), mean age 67, HR for dabigatran vs. rivaroxaban were SSE 0.92 [0.67-1.26], MB 0.59 [0.39-0.90], death 0.84 [0.65-1.11]. In RD patients (7639 per arm), mean age 80, HR for dabigatran vs. rivaroxaban were SSE 0.73 [0.59-0.94], MB 0.74 [0.57-0.96], death 0.95 [0.83-1.09]. In conclusion, at either dose dabigatran had similar or better effectiveness than rivaroxaban, but lower bleeding risk. Death rates were not different. This article is protected by copyright. All rights reserved.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enComparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation
dc.title.alternativeClin Pharmacol Theren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/cpt.1318en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30499605en_US
bordeaux.journalClinical Pharmacology and Therapeuticsen_US
bordeaux.page1439-1455en_US
bordeaux.volume105en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03209375
hal.version1
hal.date.transferred2021-04-27T08:46:16Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Pharmacology%20and%20Therapeutics&rft.date=2019&rft.volume=105&rft.issue=6&rft.spage=1439-1455&rft.epage=1439-1455&rft.eissn=1532-6535%20(Electronic)%200009-9236%20(Linking)&rft.issn=1532-6535%20(Electronic)%200009-9236%20(Linking)&rft.au=BLIN,%20Patrick&DUREAU-POURNIN,%20C.&COTTIN,%20Y.&BENICHOU,%20Jacques&MISMETTI,%20P.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée